SEC Form 4 · accession 0001104659-18-054853
Adaptimmune Therapeutics PLC · ADAP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gwendolyn Knowlton Binder-Scholl
Officer — Chief Technology Officer
Period of report
Aug 29, 2018
Accepted (ET)
Aug 31, 2018 · 8:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621227
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| American Depositary SharesF1,F2 | Aug 29, 2018 | S | 25,000 | $10.25 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ordinary shares were obtained from the exercise of share options granted on March 20, 2015. The exercise of share options and the sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2018.
- F2The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $10.15 to $10.41, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.